
Semaglutide Shows Promise in Treating Fatty Liver Disease
A phase 3 clinical trial reveals semaglutide, the active ingredient in Ozempic and Wegovy, effectively treats Metabolic Dysfunction-Associated Steatohepatitis (MASH), a serious fatty liver disease. Over 62% of patients receiving weekly semaglutide showed improvement, compared to 34% in the placebo group. The drug also reduced liver fibrosis. ...








